Histogenics, Ocugen reverse merge to create public ophthalmic-focused gene therapy development firm
- Gene Therapy, Cell Therapy
- Includes Contract
- Acquisition of Private Biotech
- Intra-Biotech Deal
- Includes Earnout
- Payment Includes Stock
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.